{
  "pmcid": "7616465",
  "sha256": "30d030dd3d62c351c64cbe444c0dacad015a73cc3a43d354d4e5509c0bb8192b",
  "timestamp_utc": "2025-11-10T00:07:04.304405+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 14.046591549295776,
    "reading_ease": 19.64735211267606,
    "word_count": 213
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "A Randomised Controlled Trial of Delayed Autologous Treg Therapy in Kidney Transplant Recipients"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Participants were randomized to receive either Treg therapy at 26 weeks post-transplantation with tacrolimus weaning or standard immunosuppression with tacrolimus and mycophenolate mofetil."
      },
      "Participants": {
        "score": 2,
        "evidence": "Conducted at a single center in the UK, the trial included first-time kidney transplant recipients, excluding high immunological risk patients."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants were randomized to receive either Treg therapy at 26 weeks post-transplantation with tacrolimus weaning or standard immunosuppression with tacrolimus and mycophenolate mofetil."
      },
      "Objective": {
        "score": 1,
        "evidence": "The study aimed to determine if this approach could enable safe immunosuppression minimization to tacrolimus monotherapy."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was graft survival and acute rejection-free survival within 18 months."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomization was computer-generated, and allocation was concealed."
      },
      "Blinding": {
        "score": 0,
        "evidence": "Blinding was not applied."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "Seven participants were randomized, with three receiving Treg therapy."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "All participants completed the study."
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "Graft survival was 100% in both groups, and acute rejection-free survival was 100% in the Treg group."
      },
      "Harms": {
        "score": 1,
        "evidence": "No severe adverse events were reported, although one Treg recipient experienced transient proteinuria, and one control experienced tacrolimus toxicity."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: ISRCTN11038572."
      },
      "Funding": {
        "score": 1,
        "evidence": "The study was funded by institutional grants."
      }
    },
    "total_score": 18,
    "max_score": 25
  }
}